Physician profile
William Grover
NPI 1598023228
$1,760.30
in general payments reported to CMS, 2019-2025
22 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $102 · 2021: $121 · 2022: $418 · 2023: $111 · 2024: $313 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $778 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $777.90 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $408.68 | 2019-2025 | Clareon, Hydrus Microstent, Rocklatan |
| Mallinckrodt Hospital Products INC. | $299.92 | 2021-2025 | Acthar |
| Biotissue Holdings INC. | $209.59 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $108.71 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $88.79 | 2020-2025 | |
| Dompe US, INC. | $82.94 | 2019-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $67.85 | 2023-2025 | Xiidra, Miebo |
| Thea Pharma INC. | $60.48 | 2022-2025 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $60.37 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $59.83 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $47.66 | 2019-2021 | |
| Astellas Pharma US INC | $44.68 | 2024 | Izervay |
| Shire North American Group INC | $35.87 | 2019 | |
| Ocular Therapeutix, INC. | $32.69 | 2020-2024 | Dextenza |
| Rxsight INC | $26.78 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $23.33 | 2022 | |
| Abbvie INC. | $21.48 | 2025 | |
| Omeros Corporation | $19.39 | 2019 | |
| Oyster Point Pharma, INC. | $16.18 | 2022 | |
| Allergan, INC. | $15.50 | 2020 | |
| Kala Pharmaceuticals, INC. | $15.26 | 2021 | |
| Sight Sciences, INC. | $14.32 | 2024 | Omni Surgical System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Grover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.